Z Contains A Cyclopentyl Or Cyclopentene Ring Patents (Class 514/530)
-
Patent number: 8278288Abstract: Organosiloxanes containing ester derivatives of ascorbic acid are disclosed having the formula (RiSiO)11Ro-Ii)Si—X-A wherein R is an alkyl group containing 1 to 6 carbon atoms, n is 1 to 3 inclusive, X is a divalent organic linking group, A is an ester derivative of ascorbic acid. A method of making an organosiloxane containing ester derivatives of ascorbic acid and the products prepared according to the method arc also taught. The compounds and compositions of the present disclosure are useful to affect tissue lightening when applied topically to keratinaceous tissue.Type: GrantFiled: September 16, 2008Date of Patent: October 2, 2012Assignee: Dow Corning CorporationInventors: Michael Salvatore Ferritto, Eric Jude Joffre, Margo L. McIvor, Michael Stephen Starch
-
Patent number: 8278353Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein.Type: GrantFiled: February 10, 2012Date of Patent: October 2, 2012Assignee: Allergan, Inc.Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
-
Publication number: 20120245205Abstract: A method for inhibiting hair growth in mammals using compositions containing FP receptor antagonists (e.g., prostaglandin F analogs that are block activation of the FP receptor). The compositions can be applied topically to the skin and/or hair. The compositions can arrest hirsutism or hypertrichosis, reverse hirsutism and hypertrichosis, and further prevent hair growth. These compositions can also be used to protect hair from chemical or radiation-induced alopecia or hair loss. These compositions can also be used to inhibit pigmentation of the hair or skin.Type: ApplicationFiled: July 29, 2010Publication date: September 27, 2012Inventors: Mitchell A. Delong, Elise A. Olsen
-
Publication number: 20120245227Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.Type: ApplicationFiled: April 9, 2012Publication date: September 27, 2012Inventor: Bhagwati P. Kabra
-
Publication number: 20120241532Abstract: Disclosed herein are insect repellant formulations and dispensing systems which avoid the need for synergists while still using highly effective pyrethrin repellant compounds. The formulations preferably are presented in aerosol form.Type: ApplicationFiled: March 24, 2011Publication date: September 27, 2012Inventors: Kent M. Palkki, Murthy S. Munagavalasa
-
Publication number: 20120232139Abstract: The present invention provides a composition for ocular topical administration for treating ocular hypertension and glaucoma, comprising latanoprost as an active ingredient, and (a) a polyol and/or sugar alcohol, (b) a nonionic surface active agent, and (c) an edetic acid compound. The composition of the present invention comprises lower amount of preservatives such as benzalkonium chloride comparative to the conventional product and therefore, can reduce incidence of the adverse side effects caused by the preservatives. In addition, the composition of the present invention can be stored stably at room temperatures for a long term.Type: ApplicationFiled: September 1, 2010Publication date: September 13, 2012Inventors: Ryuji Ueno, Junichi Kawasaki, Tadashi Hayashi
-
Publication number: 20120225938Abstract: The present invention provides a method for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin compound to a subject in need thereof. The invention also provide novel 11-deoxy-prostaglandin compound.Type: ApplicationFiled: May 14, 2012Publication date: September 6, 2012Applicant: SUCAMPO AGInventor: Ryuji UENO
-
Publication number: 20120225939Abstract: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.Type: ApplicationFiled: November 19, 2010Publication date: September 6, 2012Applicant: NOVAGALI PHARMA SAInventors: Jean-Sebastien Garrigue, Frederic Lallemand, Philippe Daull, Christophe Baudouin
-
Patent number: 8252788Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof are disclosed, wherein a dashed line represents the presence or absence of a bond; and, wherein Y, A, R, D, and n are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: May 13, 2009Date of Patent: August 28, 2012Assignee: Allergan, Inc.Inventors: David W. Old, Vinh X. Ngo
-
Patent number: 8227507Abstract: Novel ligand compounds having the general formula (I): and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.Type: GrantFiled: July 23, 2010Date of Patent: July 24, 2012Assignee: Galderma Research & DevelopmentInventors: Thibaud Biadatti, Laurence Dumais, Catherine Soulet, Sandrine Talano, Sebastien Daver
-
Publication number: 20120184615Abstract: A pharmaceutical delivery device, such as a suppository or pessary, comprises a synthetic prostaglandin PGE1 analogue (e.g. misoprostol) in a solid polyurethane hydrogel. The polyurethane is either linear or cross-linked.Type: ApplicationFiled: March 26, 2012Publication date: July 19, 2012Inventor: Steven Robertson
-
Publication number: 20120184552Abstract: The invention provides an aqueous eye drop containing latanoprost, a surfactant, and an aliphatic mono- or di-carboxylic acid having a carbon number of 3-10 or a salt thereof. In addition, the invention provides a method of suppressing adsorption of latanoprost to a resin in an aqueous solution, by adding a surfactant and an aliphatic mono- or di-carboxylic acid having a carbon number of 3-10 or a salt thereof.Type: ApplicationFiled: September 17, 2010Publication date: July 19, 2012Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Tomoko Nakajima, Wakiko Asayama, Tetsuya Tajika
-
Publication number: 20120165293Abstract: The presently disclosed subject matter provides a method of synthesizing prostaglandins and prostaglandin analogs comprising the ring closing metathesis of compounds of Formula (I). Also provided are novel compounds of Formula (I) and Formula (II). In addition to their use as synthetic intermediates in the presently disclosed methods, compounds of Formula (II) can be used as prostaglandin and/or prostaglandin analog prodrugs.Type: ApplicationFiled: July 13, 2010Publication date: June 28, 2012Inventors: George Petros Yiannikouros, Panos Kalaritis, Chaminda Priyapushpa Gamage, Stephenie Bosse Abernathy
-
Patent number: 8207223Abstract: A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).Type: GrantFiled: August 27, 2009Date of Patent: June 26, 2012Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Toru Maruyama, Kaoru Kobayashi, Tohru Kambe, Takayuki Maruyama, Hideyuki Yoshida, Akio Nishiura, Nobutaka Abe
-
Publication number: 20120149737Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor ? (RAR?) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR?, and in the treatment of diseases and conditions that are mediated by RAR?, that are ameliorated by the activation of RAR?, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.Type: ApplicationFiled: September 1, 2010Publication date: June 14, 2012Applicant: KING'S COLLEGE LONDONInventors: Jonathan Patrick Thomas Corcoran, Sarkis Barret Kalindjian, Alan David Borthwick, David Reginald Adams, Jane Theresa Brown, David Michel Adrien Taddei, Jason John Shiers
-
Publication number: 20120149736Abstract: Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ?CH— or ?N—; W is —CH?CH— Or —CH2CH2—; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intra-cellular carboxylesterase enzymes to a carboxylic acid group; R2 and R3 are selected from the side chains of a natural or non-nat-ural alpha amino acid, provided that neither R2 nor R3 is hydrogen, or R2 and R3, taken together with the carbon to which they are attached, form a 3-6 membered saturated cycloalkyl or heterocyclyl ring; Y is a bond, —C(?O)—, —S(?O)2—, —C(?O)O—, —C(?O)NR?—, —C(?5)—NR?, —C(?NH)NR? or —S(?O)2NR — wherein R? is hydrogen or optionally substituted C1—C6 alkyl; L1 is a divalent radical of formula —(Alk1)m,(Q)n(Alk2)p— wherein m, n, p, Q, Alk1 and Alk2 are as defined in the claims; X1 represents a bond; —C(?O); or —S(?O)2—; —NR4C(?O)—, —C(?O)NR4—,— NR4C(?O)NR5—, —NR4S(?O)2—, or —S(?O)2NR4— wherein R4 and R5 are independently hydrogen or optionally substituted C1Type: ApplicationFiled: February 25, 2010Publication date: June 14, 2012Applicant: Chroma Therapeutics Ltd.Inventors: Alastair David Graham Donald, David Festus Charles Moffat, Andrew James Belfield, Carl Leslie North, Stewart Andrew Wayne Jones
-
Publication number: 20120149655Abstract: A formulation or composition contractility comprising jasmonate for modulating bladder and/or treating bladder dysfunction, particularly an overactive bladder in a mammal, particularly a human and use of jasmonate for treating bladder dysfunction is provided.Type: ApplicationFiled: December 9, 2011Publication date: June 14, 2012Applicant: BROADY HEALTH SCIENCES, LLCInventor: Brunde Broady
-
Publication number: 20120142684Abstract: The disclosure provides compositions and methods for treating a skin blemish. The compositions comprise a therapeutically effective amount of a compound useful for treating skin blemishes such as wounds, scars and wrinkles.Type: ApplicationFiled: November 29, 2011Publication date: June 7, 2012Applicant: ALLERGAN, INC.Inventors: Robert M. Burk, Wha Bin Im, Scott M. Whitcup
-
Publication number: 20120136011Abstract: The disclosure provides compositions and methods for treating a skin blemish. The compositions comprise a therapeutically effective amount of a compound useful for treating skin blemishes such as wounds, scars and wrinkles.Type: ApplicationFiled: July 29, 2011Publication date: May 31, 2012Applicant: ALLERGAN, INC.Inventors: Guang L. Jiang, Wha-Bin Im, Frederick C. Beddingfield, Larry A. Wheeler, Scott M. Whitcup, Robert M. Burk
-
Publication number: 20120135984Abstract: Provided are compounds, compositions, and methods for treating diseases and conditions wherein an inhibitor of a kinase, such as rho kinase (ROCK), and an inhibitor of one or more of the monoamine transporters, such as NET or SERT, act in concert to improve the condition.Type: ApplicationFiled: May 1, 2010Publication date: May 31, 2012Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty, Geoffrey Richard Heintzelman, Jeffrey D. Yingling, Casey Kopczynski
-
Publication number: 20120129926Abstract: The invention relates to novel calcium-sensing receptor (CaSR) modulating trifluoromethylphenylene cyclopentylene compounds represented in formula (I) and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.Type: ApplicationFiled: May 26, 2010Publication date: May 24, 2012Applicant: LEO PHARMA A/SInventor: Bjarne Nørremark
-
Publication number: 20120131700Abstract: The invention provides seed treatment compositions as well as their use, methods for treating seeds, methods of protecting plants against pests and also treated seeds and plants. In one embodiment there is provided a method of treating a seed with a seed treatment composition to induce a plant resistance mechanism against one or more pests in a plant grown from said seed.Type: ApplicationFiled: January 12, 2012Publication date: May 24, 2012Applicant: Plant Bioscience LimitedInventors: Michael Richard Roberts, Nigel Duncan Paul, Jane Elizabeth Taylor, Patricia Croft, Jason Paul Moore
-
Publication number: 20120122764Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, B, X, m and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of compounds of the invention, and a combination of pharmacologically active agents and a compound of the invention.Type: ApplicationFiled: November 10, 2011Publication date: May 17, 2012Applicant: NOVARTIS AGInventors: Rajeshri Ganesh KARKI, Toshio KAWANAMI, Gary Michael KSANDER, Qian LIU, Muneto MOGI, Nikolaus SCHIERING, Robert SUN
-
Publication number: 20120122976Abstract: The invention relates to a phosphate-free pharmaceutical composition which comprises at least one FP prostanoid receptor agonist and/or at least one prostamide receptor agonist and also citrate salts and/or citric acid.Type: ApplicationFiled: May 14, 2010Publication date: May 17, 2012Applicant: URSAPHARM ARZNEIMITTEL GMBHInventor: Frank Holzer
-
Patent number: 8173685Abstract: A compound of formula (I) or of formula (II) wherein X is oxygen or sulfur, and Y is a residue of pipecolic acid or a residue of an amino acid, preferably a naturally occurring amino acid.Type: GrantFiled: July 11, 2008Date of Patent: May 8, 2012Assignee: Nabriva Therapeutics AGInventors: Klaus Thirring, Werner Heilmayer
-
Publication number: 20120107376Abstract: The present invention relates to a method for improving ocular bioavailability of latanoprost by adding an organic amine to an aqueous eye drop composition containing latanoprost. The invention further relates to an aqueous eye drop composition in which a better ocular bioavailability of latanoprost is achieved by adding an organic amine, and to a method for treating occular hypertension and glaucoma by administering said composition to a subject in need of such treatment.Type: ApplicationFiled: June 23, 2010Publication date: May 3, 2012Inventors: Timo Reunamaki, Paula Tervo, Jukka Lokkila, Pertti Pellinen, Paivi Alajuuma, Olli Oksala
-
Patent number: 8168637Abstract: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.Type: GrantFiled: January 27, 2010Date of Patent: May 1, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Edmondson, Dooseop Kim, Malcolm Maccoss, Emma R. Parmee, Ann E. Weber, Jinyou Xu
-
Patent number: 8163796Abstract: A novel treatment regimen is described for the control and elimination of cancer cell populations including cancer stem cells. The disclosed protocol consists of a pretreatment step followed by a treatment step. The pretreatment step sensitizes cancer cells to apoptosis by altering their intracellular oxidation-reduction state via reduced glutathione depletion. The treatment step involves the sequential administration of a cancerostatic dicarbonyl compound to induce apoptosis. The use of nanoparticle delivery systems further enhances both the pharmacokinetic and pharmacodynamic properties of the pretreatment compounds and the cancerostatic dicarbonyls. Since the pretreatment and treatment compounds are carefully selected and delivered, normal cells are not affected and side effects are kept to a minimum.Type: GrantFiled: July 20, 2010Date of Patent: April 24, 2012Assignee: BioChemical Solutions, LLCInventors: Morris A. Johnson, Michael M. Smits
-
Publication number: 20120088823Abstract: Provided is a composition for scalp and hair treatment, comprising a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness, or hair thinness.Type: ApplicationFiled: December 19, 2011Publication date: April 12, 2012Applicant: R-TECH UENO, LTD.Inventors: Masato IINO, Satoshi YAMAKI, Satoshi NAKANISHI, Masahiro TAJIMA, Ryuji UENO
-
Publication number: 20120083529Abstract: The present invention relates to methods of treating benign hyperproliferative diseases of the epidermis by administering a composition comprising at least one jasmonate ester derivative, preferably methyl jasmonate. In particular, the present invention provides jasmonate ester derivatives as potent compounds useful for the treatment of disorders such as actinic keratoses with reduced side effects.Type: ApplicationFiled: June 3, 2010Publication date: April 5, 2012Applicant: SEPAL PHARMA LTDInventors: Max Herzberg, Frederic Revah
-
Publication number: 20120065258Abstract: A pharmaceutical composition containing a prostaglandin and an alkanoic acid ester of a polyethoxylated sorbitol in an amount effective to enhance the chemical stability of the prostaglandin, and the use thereof for treating ophthalmic conditions. Also disclosed are methods for enhancing the chemical stability of a prostaglandin-containing composition by using an alkanoic acid ester of a polyethoxylated sorbitol.Type: ApplicationFiled: November 17, 2011Publication date: March 15, 2012Inventors: Victor Deaciuc, Michael Hagan, Hashem Heiati, Karen K. Jette, Gary C. Visor, Ian G.C. McAffer, Peter Tasko
-
Publication number: 20120058937Abstract: A new class of neuramidase inhibitor prodrugs is provided characterized by a prodrug moiety of a carboxyl group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide or a carbonyl ethoxy tripeptide, a guanidine group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide, a carbonyl ethoxy tripeptide; a primary alcohol modified to form an esterified single amino acid, dipeptide or tripeptide of zanavimir of the unaltered therapeutic agent. Exemplary therapeutic agents so modified to form prodrugs include zanavimir, oseltamivir and peramivir. The prodrug has increased oral bioavailability relative to the unaltered neuraminidase inhibitor and is effective in the inhibition of viral infections involving neuraminidase in the viral reproductive cycle.Type: ApplicationFiled: April 15, 2009Publication date: March 8, 2012Applicant: TSRL, Inc.Inventors: John Hilfinger, Gordon Amidon
-
Publication number: 20120046276Abstract: A method of preventing or treating diseases caused by Mycobacterium, comprising administering to a subject in need of such treatment an effective amount of a pleuromutilin.Type: ApplicationFiled: October 25, 2011Publication date: February 23, 2012Applicant: Nabriva Therapeutics AGInventors: Gerd Ascher, Heinz Berner, Rosemarie Mang
-
Publication number: 20120046359Abstract: Control or repellency of bed bugs by bringing the bed bugs into contact with a bed bug control formulation containing at least one compound selected from the group consisting of certain alkyl ketones and cyclic ketones wherein the total number of carbon atoms in the alkyl ketones and cyclic ketones is from 10 to 16 carbon atoms and method for achieving such control or repellency.Type: ApplicationFiled: October 27, 2011Publication date: February 23, 2012Inventor: Robert H. Bedoukian
-
Publication number: 20120040025Abstract: Methods for reducing the risk of or treating a disorder associated with fluid and/or salt retention in a patient are described. The methods include administering to the patient an agent selected from: a) an agent that reduces sodium absorption in the intestine; b) an agent that increases anion secretion in the intestine; or c) an agent that both reduces sodium absorption in the intestine and increases anion secretion in the intestine.Type: ApplicationFiled: April 23, 2008Publication date: February 16, 2012Inventors: Mark G. Currie, Daniel P. Zimmer
-
Publication number: 20120034321Abstract: The invention provides methods for treating ophthalmic disorders comprising at least one nitric oxide enhancing prostaglandin compound or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The nitric oxide enhancing prostaglandin compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group.Type: ApplicationFiled: October 18, 2011Publication date: February 9, 2012Inventor: David S. Garvey
-
Publication number: 20120028982Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: ApplicationFiled: October 7, 2011Publication date: February 2, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Akito YASUHARA, Kazunari Sakagami, Hiroshi Ohta, Atsuro Nakazato
-
Publication number: 20120029073Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.Type: ApplicationFiled: October 4, 2011Publication date: February 2, 2012Inventors: Bhagwati P. Kabra, Nuria Carreras, Mónica Cuchi, Francisco Javier Galán, Mridvika, Elena González Puig, Nuria Jiménez, Carmen Martinez
-
Publication number: 20120021013Abstract: An aqueous composition of latanoprost and SAE-CD is provided. The composition possesses improved stability over otherwise similar compositions excluding SAE-CD. Methods of and systems for treating diseases, disorders, conditions or symptoms of the eye that are therapeutically responsive to latanoprost are also provided.Type: ApplicationFiled: November 7, 2008Publication date: January 26, 2012Applicant: CyDex Pharmaceuticals, Inc.Inventors: Naomi Esaki, James D. Pipkin
-
Publication number: 20110319487Abstract: This invention concerns an ophthalmic solution including: at least one prostaglandin; a solubilizing agent; a gelling agent of the carbomer type; a carbomer polymerization-inhibiting agent; a co-gelling/co-solubilizing agent.Type: ApplicationFiled: June 28, 2011Publication date: December 29, 2011Applicant: Laboratoires THEAInventor: Fabrice Mercier
-
Publication number: 20110319488Abstract: A colloidal anionic oil-in-water emulsion includes a prostaglandin, an oil having a iodine value ?2, a surfactant and water, provided the anionic oil-in-water emulsion does not contain polyvinyl alcohol. The use of the anionic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.Type: ApplicationFiled: March 4, 2010Publication date: December 29, 2011Applicant: NOVAGALI PHARMA SAInventors: Frederic Lallemand, Betty Phillips, Jean-Sebastien Garrigue
-
Publication number: 20110313038Abstract: A colloidal cationic oil-in-water emulsion includes: —a prostaglandin, —an oil having a iodine value ?2, —one or more surfactants including at least one quaternary ammonium compound, —water, wherein the prostaglandin/total sum of surfactants mass ratio is included between 0.5 and 5. The use of the cationic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.Type: ApplicationFiled: March 4, 2010Publication date: December 22, 2011Applicant: NOVAGALI PHARMA SAInventors: Frederic Lallemand, Betty Phillips, Jean-Sebastien Garrigue
-
Publication number: 20110305731Abstract: The present invention refers to pharmaceutical compositions comprising a jasmonic acid derivative and a carrier, preferably cyclodextrin or a polyamidoamine. The compositions may be used for treating cancer.Type: ApplicationFiled: May 28, 2009Publication date: December 15, 2011Inventor: Jose Emilio Fehr Pereira Lopes
-
Publication number: 20110301164Abstract: A method is provided of treating an eye with ophthalmologically active compounds, particularly with intra-ocular pressure lowering (IOP) compounds, where a dose of 5-15 microliters is delivered at a standard concentration.Type: ApplicationFiled: August 12, 2011Publication date: December 8, 2011Inventors: BEN Z. COHEN, NIGEL KELLY
-
Publication number: 20110294880Abstract: An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F2? in a preparation containing prostaglandin F2?. The object was attained by formulating a prostaglandin F2? derivative into an oil-in-water emulsion together with an oil, for example, medium chain fatty acid triglyceride, a water-soluble polymer and water.Type: ApplicationFiled: August 10, 2011Publication date: December 1, 2011Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Yusuke SAKAI, Akira Ohtori
-
Publication number: 20110281853Abstract: The present invention provides compositions and methods for treating or preventing atrial fibrillation (AF). In particular, the present invention provides administration of muscarinic receptor antagonists (e.g., M2-selective muscarinic receptor blockers), administered alone or in combination with other therapeutic agents (e.g., beta-adrenergic receptor blockers) to treat and/or prevent atrial fibrillation.Type: ApplicationFiled: May 12, 2011Publication date: November 17, 2011Inventors: Rishi Arora, David E. Zembower
-
Publication number: 20110275711Abstract: Provided is a method for treating macular edema in a mammalian subject, comprising administering an effective amount of a fatty acid derivative to the subject in need thereof. The method of the present invention can effectively treat macular edema in a non-invasive manner. In one embodiment of the present invention, the fatty acid derivative is isopropyl unoprostone.Type: ApplicationFiled: April 12, 2011Publication date: November 10, 2011Applicant: R-TECH UENO, LTD.Inventors: Yukihiko MASHIMA, Ryuji UENO
-
Publication number: 20110245172Abstract: The present invention relates to biocompatible oligomer-polymer compositions for the in situ formation of implants, wherein the implants release a bioactive agent, a metabolite, or a prodrug thereof, at a controlled rate. The sustained release delivery system includes a flowable composition containing a bioactive agent, a metabolite, or a prodrug thereof, and an implant containing a bioactive agent, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, a biocompatible end-capped oligomeric liquid, and a bioactive agent, a metabolite, or a prodrug thereof.Type: ApplicationFiled: June 3, 2009Publication date: October 6, 2011Applicant: Tolmar Therapeutics, Inc.Inventor: Richard L. Norton
-
Patent number: 8030349Abstract: The present invention provides a method for preventing the degradation of a thermally unstable medicament in an eye drop containing the medicament thereby to stabilize the eye drop. By adding an organic amine to an eye drop containing a thermally unstable medicament, the degradation of the medicament in the eye drop can be effectively prevented, and therefore the eye drop can be stably stored.Type: GrantFiled: August 2, 2006Date of Patent: October 4, 2011Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Hiroyuki Asada, Akio Kimura
-
Patent number: RE43372Abstract: Compounds having the general structure: which are useful for the treatment of a variety of diseases and conditions, such as bone disorders.Type: GrantFiled: June 5, 2009Date of Patent: May 8, 2012Assignee: Duke UniversityInventors: Mitchell Anthony deLong, David Lindsey Soper, John August Wos, Biswanath De